Protalix BioTherapeutics (PLX) Tax Provisions (2023 - 2026)

Protalix BioTherapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 2536.28% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $3.4 million (up 129.87% YoY), while the FY2025 annual figure was $656000.0, down 46.32% from the prior year.
• Tax Provisions was $2.8 million for Q1 2026 at Protalix BioTherapeutics, up from $565000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $3.4 million in Q2 2023 to a low of -$175000.0 in Q3 2025.
• Historically, Tax Provisions has averaged $863846.2 across 4 years, with a median of $266000.0 in 2025.
• The sharpest annual moves came in 2024 and 2026: Tax Provisions plunged 170.77% in 2024, then soared 2536.28% in 2026.
• A 4-year view of Tax Provisions shows it stood at $2.7 million in 2023, then slumped by 60.96% to $1.1 million in 2024, then tumbled by 46.6% to $565000.0 in 2025, then soared by 387.26% to $2.8 million in 2026.
• The last three Tax Provisions figures came in at $2.8 million (Q1 2026), $565000.0 (Q4 2025), and -$175000.0 (Q3 2025), per Business Quant data.